Clinical variables.
| Variables | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5* | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, yrs | 43 | 38 | 37 | 27 | 49 | 49 | 43 | 45 | 42 | 51 | 63 | 42 |
| Sex | M | M | M | M | M | M | F | F | M | F | M | F |
| Weight, kg | 82 | 92 | 127 | 88 | 91 | 87 | 91 | — | 81 | 68 | 70 | 82.5 |
| PsA duration, yrs | 1 | 2 | 10 | 1 | 6 | 20 | 25 | 13 | 10 | 3 | 6 | 2 |
| Current DMARD and dose | MTX 20 mg weekly | MTX 25 mg weekly | MTX 20 mg weekly | MTX 20 mg weekly | SSZ 2 g/daily | MTX 25 mg weekly | HCQ 100 mg daily | NIL | NIL | NIL | LEF 20 mg daily, MTX 15 mg weekly | MTX 10 mg weekly, SSZ 2 mg daily |
| bDMARD | ETN | ADA | ADA | ADA | ADA | ETN | ADA | ADA | IFX | IFX | IFX | IFX |
| Current PRED | 0 | 0 | 0 | 5 mg daily | 7.5 mg daily | 0 | 10 mg daily | 0 | 0 | 0 | 0 | 0 |
| TJC baseline/Week 12, 68 joints | 3/0 | 6/2 | 4/0 | 5/0 | 11 | 4/2 | 27/1 | 13/8 | 1/0 | 4/0 | 4/0 | 14/17 |
| SJC baseline/Week 12, 66 joints | 9/3 | 10/4 | 9/5 | 4/3 | 10 | 8/8 | 13/7 | 8/5 | 22/11 | 10/1 | 10/8 | 5/9 |
| DAS28-ESR baseline/Week 12 | 3.30/1.55 | 3.79/2.51 | 4.04/1.13 | 2.89/0.51 | — | 4.75/2.09 | 4.63/2.1 | 4.69/3.94 | 2.99/0.68 | 4.45 | 4.36/1.75 | 3.31/3.66 |
| DAS28-CRP baseline/Week 12 | 2.53/1.96 | 3.90/2.23 | 2.82/0.64 | 2.40/0.51 | — | 4.52/2.09 | 3.87/1.52 | 3.81/3.17 | 2.32/0.93 | 3.51 | 3.24/0.53 | 3.81/NIL |
| Dactylitis scores/baseline | 0 | 21 | 41 | 30 | 1 | 52 | 73 | 52 | 90 | 10 | 7 | 40 |
↵* One subject withdrew from the study after consent and baseline clinical data collection (patient 5).
PsA: psoriatic arthritis; DMARD: disease-modifying antirheumatic drug; bDMARD: biologic DMARD; PRED: prednisolone; TJC: tender joint count; SJC: swollen joint count; DAS28: 28-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; NIL: none; LEF: leflunomide; ETN: etanercept; ADA: adalimumab; IFX: infliximab.